People suffering from multiple sclerosis must endure a combination of therapies that have dangerous side effects and often require periodic visits to a hospital.
The company has conducted clinical trials on BG-12, a combination treatment that helps patients avoid flare ups of multiple sclerosis symptoms, CBS News noted.
Results from those trials, involving 2,000 patients over two years, were published in the New England Journal of Medicine.
Patients taking BG-12 experienced half as many symptom relapses as those taking a placebo. They also showed 70% less brain scarring when examined with MRIs.
BG-12 is awaiting approval from the FDA.
Shares of Biogen Idec were fractionally higher in Thursday morning trading.
Multiple sclerosis tends to strike during adulthood. More than 400,000 Americans are currently battling the disease.